(UroToday.com) The bladder cancer non-invasive session at the 2021 American Urologic Association (AUA) annual meeting included a presentation by Dr. Vidit Sharma discussing adverse events after transurethral resection of intermediate-risk non-muscle-invasive bladder cancer (NMIBC). Transurethral resection of bladder tumor (TURBT) is a common urologic procedure with a reported 30-day complication rate of about 6% according to NSQIP data.1 However, such data sources may underestimate the frequency of “adverse events” that are not easily classified using administrative codes and do not usually account for co-occurring adverse events. At today’s session, Dr. Sharma and colleagues presented the results of their study analyzing TURBT-associated adverse events from a prospective cohort of intermediate-risk NMIBC patients, a subgroup with a highly variable prognosis.